Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Can genomic alterations be used to inform radiotherapy dosage?

Amy Xu • 31 May 2026
ASCO 2026
General

Amy Xu, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, explores how genomic alterations could be used to inform radiation dosage, which was the focus of a Phase II trial (NCT05010031) of palliative doses to metastatic solid tumors. To improve applicability, a follow-up study is being conducted for more definitive doses of radiotherapy where toxicities can limit treatment. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amy Xu

Reduced-dose radiation achieves local control in ATM-mutated cancers: Phase II results
1:26
Reduced-dose radiation achieves local control in ATM-mutated cancers: Phase II results
Amy Xu • 31 May 2026

Related Videos

CLIO-8221: a novel anti-HER2 dual payload ADC conjugated to TOP1i and ATRi
4:36
CLIO-8221: a novel anti-HER2 dual payload ADC conjugated to TOP1i and ATRi
Timothy Yap • 4 Jun 2026
Werner helicase inhibitors: looking beyond immunotherapy for MSI tumors
10:50
Werner helicase inhibitors: looking beyond immunotherapy for MSI tumors
Timothy Yap • 4 Jun 2026
YOCAS, mood disturbance and insomnia in cancer survivors
1:19
YOCAS, mood disturbance and insomnia in cancer survivors
Karen Mustian • 30 May 2026
Does YOCAS produce long-term benefits in mood disturbances and insomnia in cancer survivors?
0:45
Does YOCAS produce long-term benefits in mood disturbances and insomnia in cancer survivors?
Karen Mustian • 30 May 2026
The content of VJOncology is intended for healthcare professionals